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The Fifth Decennial International 
Conference on Healthcare-Associated 
Infections, held March 2010 in At-
lanta, Georgia, USA, brought the is-
sue of antimicrobial drug resistance 
to the forefront. Results of a survey 
that polled members of the Society for 
Healthcare Epidemiology of America 
regarding critical knowledge gaps and 
research priorities were presented. 
Respondents reported that 3 of the 5 
most important issues they face are 
directly associated with antimicrobial 
drug resistance: multidrug–resistant 
gram-negative bacteria, antimicrobial 
stewardship, and methicillin-resistant 
Staphylococcus aureus (MRSA).
The publication of this collection 
of authoritative reviews of these is-
sues is therefore timely. This concise 
volume draws on the knowledge of 
23 authors, many of whom are either 
current or past staff members of the 
Centers for Disease Control and Pre-
vention. In 10 chapters and 174 pages, 
these authors address contemporary is-
sues in bacterial, fungal, parasitic, and 
viral (HIV) resistance, as well as some 
aspects of the effects of antimicrobial 
drug resistance on healthcare facili-
ties. The main emphasis of the book is 
on the epidemiology and mechanisms 
and public health implications of resis-
tant pathogens, not on details of treat-
ment. Chapters on MRSA, extended-
spectrum  β-lactamase–producing 
gram-negative bacteria, and ﬂ  uoroqui-
nolone resistance cover the epidemi-
ology and mechanisms of resistance, 
laboratory detection, and treatment 
considerations. A historical review 
of the contribution of bacterial pneu-
monia to the death rate of previous 
inﬂ  uenza pandemics clearly discusses 
the likelihood and consequences of 
resistance in strains of Streptococcus 
pneumoniae and S. aureus. Questions 
raised here about how these antimi-
crobial drug–resistant bacteria affect 
a modern pandemic, such as the im-
pact of antiviral drugs and diagnostic 
testing on antibiotic use, can now be 
investigated in light of the subsequent 
pandemic (H1N1) 2009.
Three chapters address resistance 
in healthcare settings and the promo-
tion of appropriate antimicrobial drug 
use. The ﬁ  rst describes interventions 
to reduce the inappropriate use of 
antimicrobial agents for respiratory 
conditions and quality initiatives that 
can improve prescribing. The chap-
ter that reviewed effective strategies 
for controlling resistant pathogens in 
hospitals is the only chapter that was 
not well referenced on some of the 
more controversial issues, such as sil-
ver coating of devices. However, the 
chapter on estimating costs attribut-
able to infections caused by antimi-
crobial drug–resistant bacteria is com-
prehensive.
Three  ﬁ   nal chapters expand the 
scope of this volume into issues of 
parasitic, fungal, and viral resistance. 
Resistance in helminths is presented 
in the context of mass treatment dur-
ing eradication programs and the need 
for enhanced surveillance programs. 
The chapter on antifungal resistance 
reviews available drugs and labora-
tory detection of resistance. The ﬁ  nal 
chapter on HIV drug resistance in the 
developing world reviews initial con-
cerns and current encouraging data 
on antiretroviral drug–resistance in 
sub-Saharan Africa and southern Asia. 
Current public health strategies for de-
tecting and controlling drug–resistant 
HIV are given, along with a clear ac-
count of the biological and pharmaco-
logic factors that affect HIV resistance 
and a review of areas needing contin-
ued attention and resources.
The strength of this book is the 
wide scope of its coverage of antimi-
crobial drug resistance. Most chapters 
are well written in a succinct style and 
format easily accessible to the gen-
eral reader. The text has supportive 
references from primary sources, and 
contains a good index. This book is a 
valuable resource for those beginning 
their careers or who are looking for a 
research focus, or for anyone already 
an expert in an aspect of antimicrobial 
resistance who is seeking a broader 
perspective. 
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A great story has drama, mys-
tery, conﬂ   ict, interesting characters, 
intrigue, and excitement. The story 
of tuberculosis (TB) has all of these. 
It is a story of epic proportions. Carol 
Dyer’s Tuberculosis (Biographies of 
Disease) is not a textbook or a history 
book; it tells us the story of this fasci-
nating but deadly disease.
Dyer, a science writer, takes us 
from the mummies of ancient Egypt, 
with their visible signs of TB, to the 
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skepticism that met Robert Koch’s 
discovery of the tubercle bacillus, to 
today’s global TB public health emer-
gency. Thought by many to be a dis-
ease of the past, the ﬁ  nal chapters of 
the book jolt us into today’s reality.
As the drama unfolds, Dyer de-
scribes how TB ravaged Europe’s 
working class during the industrial 
revolution. More personal accounts 
from the Romantic Age are espe-
cially interesting. She tells us how 6 
siblings of the famed literary Bronte 
family died of TB. She describes the 
tragic death from TB of the poet John 
Keats at age 26. And the personal an-
ecdotes continue; from the scientists 
who advanced our knowledge of TB 
to the artists whose lives and art were 
affected. By describing its inﬂ  uence 
on literature and the arts, Dyer brings 
to life the profound effects of TB on 
humanity.
Her discussion of the victories 
and setbacks in the ﬁ  ght against TB 
provide a context for what she consid-
ers to be the story’s main plot: how is 
it possible that TB remains a leading 
cause of death from infectious disease 
globally? Her description of the com-
plex biology of the organism and the 
societal characteristics of the disease 
help us understand why, despite the 
discovery of effective chemotherapy, 
TB continues to devastate.
The ﬁ  nal chapters provide a sober-
ing picture of the current state of TB. 
Dyer describes the serious effect of 
the HIV epidemic on TB and warns of 
the alarming rates of more dangerous 
forms of drug-resistant TB. However, 
the story she tells ultimately becomes 
a hopeful one. She discusses how the 
world community has come together, 
leading to new funding initiatives and 
prevention and control strategies.
This book is a quick and easy 
read (120 pages). However, the orga-
nization of its 8 chapters is peculiar. 
The reader might be tempted to skip to 
the third chapter on the history of TB 
or even stop reading, as he or she get 
bogged down in some of the medical 
details in the ﬁ  rst 2 chapters. Occa-
sional overuse of technical detail gets 
in the way of the story. Sidebars with 
anecdotes and scientiﬁ  c  summaries, 
scattered throughout, are a nice ad-
dition to the format of the book. The 
timeline at the end is also helpful.
The book falls short in describing 
the epidemiology of TB. More quanti-
tative information would provide the 
reader with a better understanding of 
the magnitude of the problem. Despite 
this issue and several minor technical 
inaccuracies, the book is informative 
and at times exciting. It captures all 
the elements of this great story. Over-
all, this book is a great read for pub-
lic health professionals and the gen-
eral public. For the reader engaged in 
global public health efforts, the book 
should be a call to action.
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